AZ new crown vaccine real world data released, one shot reduces the risk of illness and hospitalization in the elderly

As a number of new crown vaccines are authorized to be used around the world, data on vaccines to prevent COVID-19 in the real world are also emerging.

Today, Public Health England (PHE) announced for the first time the real-world preventive efficacy data of the new crown vaccine ChAdOx1 (also known as AZD1222) jointly developed by AstraZeneca and Oxford University.

The United Kingdom authorized the new crown vaccine BNT162b2 for emergency use in the UK on December 8 last year, and authorized the emergency use of the new crown vaccine ChAdOx1 on December 30.

In this study, researchers evaluated the risk of COVID-19 in the elderly who received a dose of BNT162b2 or ChAdOx1 after January 4 this year.

Through the analysis of the data, the researchers found that in the elderly over 70 years old, the risk of contracting COVID-19 began to decrease 14 days after receiving a dose of ChAdOx1 vaccine, and the protective effect of the vaccine was more than 35 days after vaccination.

For BNT162b2, 10-13 days after a dose of the vaccine, the risk of contracting COVID-19 begins to decrease.

▲The risk ratio of COVID-19 in the elderly over 70 years old at different time periods after a dose of BNT162b2 or ChAdOx1 vaccine (compared with the unvaccinated control population, picture source: reference [2])

In addition, among COVID-19 patients who tested positive for nucleic acid, the risk of vaccinated patients that the disease progressed to requiring hospitalization was further reduced by about 40% compared with unvaccinated patients.

Dr.

Reference materials:

[1] Gou et al.

[2] Patsoukis et al.

[3] Hu et al.

[4] Cotton et al.